L i n k to o r i g i n a L a rt i c L e
We read with great interest the Opinion article by Jamie Fletcher and colleagues, ABC transporters in cancer: more than just drug efflux pumps. Nature Rev. Cancer. 10, 147-156 (2010), recently published in Nature Reviews Cancer 1 . The authors underline innovative aspects regarding the role of ATP binding cassette (ABC) transporters that -besides contributing to drug resistance 2 -seem to be important for the development of tumours. Accumulating evidence shows that the expression of specific ABC transporters is associated with tumourinitiating cells and cancer stem cells (CSCs) 3 , implying that the limited efficacy of chemotherapy might reflect the failure to eliminate CSC-expressing ABC transporters. However, expression by CSC would not necessarily mean that ABC transporters are implicated in cancer initiation and/or progression because their expression might be controlled by other proteins that function as master regulators. Nonetheless, ABC transporter expression has been correlated with progression and a more aggressive tumour phenotype 4, 5 . In addition to these concepts, we think that post-translational modifications of ABC transporters, specifically glycosylation, is an important field of reasearch 6 through which new insights into the function of ABC transporters in tumorigenesis should be forthcoming. That glycosylation defects on ABC transporters, in particular ABCC1 (also known as MRP1), have consequences has been provided by a study showing the mislocalization of multidrug transporters in cisplatin-resistant cancer cell lines 7 . Interestingly, glycosylation might regulate ABC transporter levels, as altered glycosylation of ABCG2 (also known as BCRP) results in increased degradation 8 . Indeed, N-linked glycans are thought to be crucial regulators of the stability of ABCG2 in the endoplasmic reticulum 8, 9 . In fact, N-glycosylated wildtype ABCG2 is degraded in lysosomes, whereas misfolded mutant proteins have been shown to undergo ubiquitin-mediated degradation in the proteasome 10, 11 . We have recently observed that increased levels of glycosylation-defective ABCC1 and ABCC4 are associated with resistance to platinum compounds in ovarian carcinoma cell lines 12 . This phenotype is not due to mutations in the putative N-glycosylation sites of these transporters, but is instead related to the reduced expression of two glycosyltransferases, GNPTG (which accounts for the first step in the biosynthesis of N-glycans) and MGAT5 (which catalyses the addition of mannose to proteins). In keeping with this, a protective role has been ascribed to the glycosylation of ABCB1 (also known as P-glycoprotein), which can be shut down by statins 13 , thereby suggesting new therapeutic options. Therefore, we propose that glycosylation is a relevant regulatory mechanism of ABC transporter expression and should be considered so that we can better understand the contribution of transporters to both drug resistance and tumour initiation and progression.
